Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. - In patients suffering from chronic kidney disease, with or without type 2 diabetes, researchers investigated the impact of dapagliflozin. Using randomization, a total of 4,304 participants were assigned to receive dapagliflozin (10 mg once daily) or placebo. The participants were patients with an estimated glomerular filtration rate (GFR) of 25 to 75 ml per minute per 1.73 m² of body-surface area and a urinary albumin-to-creatinine ratio (with albumin recorded in milligrams and creatinine in grams) of 200 to 5,000. A composite of a sustained decrease in the estimated GFR of at least 50%, end-stage kidney disease, or death from renal or cardiovascular causes was the primary outcome. Findings revealed that a significantly lower risk of this composite outcome was observed in relation to treatment with dapagliflozin vs with placebo, irrespective of the presence or absence of diabetes, in patients with chronic kidney disease. The primary outcome event occurred in 197 of 2,152 participants (9.2%) in the dapagliflozin group and 312 of 2,152 participants (14.5%) in the placebo group